shadow shadow shadow shadow shadow
    Country
    Opportunity Status
    Funding Instrument Type
    Category
    Clear

    High-Impact HIV Prevention and Surveillance Programs for Health Departments: Accelerating Pre-Exposure Prophylaxis (PrEP) Uptake for Ending the HIV Epidemic in the United States

    CDC-RFA-PS-24-00470101SUPP24

    Centers for Disease Control - NCHHSTP

    Opening date 1 Aug 2024, 12:00AM

    Closing date 31 Aug 2024, 12:00AM

    Funding Opportunity Number: CDC-RFA-PS-24-00470101SUPP24

    Opportunity Category: Discretionary

    Expected Number of Awards: 4

    CFDA Number(s): 93.940 -- HIV Prevention Activities Health Department Based

    Cost Sharing or Matching Requirement: No

    Posted Date: Aug 01, 2024 12:00:00 AM EDT

    Closing Date: Aug 31, 2024 12:00:00 AM EDT

    Closing Date Details: Electronically submitted applications must be submitted no later than 11:59 pm ET on the listed application due date.

    Estimated Total Program Funding: 1750000

    Eligible Applicants: Special district governments,County governments,State governments,City or township governments

    Additional Information on Eligibility: Due to statutory authority, this supplemental funding opportunity is offered to the 32 state, local and territorial health departments currently receiving Ending the HIV Epidemic in the U.S. (EHE) funding under notice of funding opportunity (NOFO) PS24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments.

    Agency Name: Centers for Disease Control - NCHHSTP

    Description: CDC announces the availability of approximately $7 million in competitive supplemental funding for the 32 health department jurisdictions currently receiving Ending the HIV Epidemic in the US (EHE) initiative funding resources under notice of funding opportunity (NOFO) PS24-0047: High-Impact HIV Prevention and Surveillance Programs for Health Departments. Fully aligned with PS24-0047, the supplemental NOFO prioritizes acceleration of progress toward achieving the national HIV prevention goal of 50% pre-exposure prophylaxis (PrEP) coverage by the end of 2025. Jurisdictions with greater need for PrEP and lower uptake among priority populations disproportionately affected by HIV and low PrEP prescriptions (i.e., Black and Latino gay, bisexual, and other men who have sex with men (MSM), and Black cisgender and transgender women) need these additional resources and flexibility to accelerate PrEP uptake through patient navigation/case management services and improve access to and utilization of existing PrEP services not covered by other financial resources. Recipients will implement enhanced and expanded programmatic activities to increase access to and uptake of PrEP for priority populations and to help further eliminate structural and social barriers that prevent equitable access to PrEP within EHE jurisdictions. Additionally, these enhanced and expanded PrEP programs will incorporate elements to increase HIV non-occupational post-exposure prophylaxis (PEP) and doxycycline post-exposure prophylaxis (doxy PEP) awareness and access, including activities with clinicians, non-clinical community-based organizations (CBOs), and persons at risk for HIV acquisition.The supplemental NOFO's period of performance is September 30, 2024 - May 31, 2025 (8 months). Recipients may request to continue implementation of supplemental programmatic activities during PS24-0047 Budget Year 2 (June 1, 2025 - May 31, 2026). Recipients will implement concurrently all required programmatic activities as described in both PS24-0047 and the forthcoming supplemental NOFO.

    Grantor Contact Information: Erica K. Dunbar NOFOINFO@cdc.gov

    We use cookies and similar technologies that are necessary to operate the website.Please read our cookie policy.

    We use cookies and similar technologies that are necessary to operate the website. Additional cookies are only used with your consent. We use the additional cookies to perform analyses of website usage and to check marketing measures for their efficiency. These analyses are carried out to provide you with a better user experience on the website. You are free to give, deny, or withdraw your consent at any time by using the "cookie settings" link at the bottom of each page. You can consent to our use of cookies by clicking "Agree". For more information about what information is collected and how it is shared with our partners, please read our cookie policy.

    • Required to run the website
    • Monitoring website usage and optimizing the user experience
    • Evaluation of marketing actions
    • Storage of your preferences from previous visits
    • Collecting user feedback to improve our website
    • Recording of your interests in order to provide customised content and offers
    Cookie Settings Accept